At long last China’s CFDA is moving on exemption of IVDs from in China trials with publication of a first list of Class II diagnostics proposed for approval without in-China clinical data.
On 17th May 2017, China FDA published a draft ‘Exemption List of Local Clinical Trial for Class II & Class III medical devices’. This is open for industry and user feedback with a deadline of 20th June 2017.
This will be the 3rd wave exemption list in China.
Although the Europeans have retained risk classifications and 3rd party conformity assessment based on risk class, the new MDR changes almost everything. In more than ten times as many words as the MDD and AIMD, the new regulations provide much more detailed requirements and set a higher bar especially in clinical evidence, postmarket monitoring and risk management, integrating all of these into a single living process. The race is on for the three year transition period – it’s going to get busy…
Last week, the Australian Therapeutic Goods Administration (TGA) published the final guidelines on Clinical Evidence for devices. The guidelines reiterate key elements of clinical evaluation that are often missing from Clinical Evidence Reports. The guidelines also provide specific requirements for certain high risk devices.
Hot off the press! On 30th September 2016, China FDA published its final “Exemption list for Class II and Class III medical devices for local clinical study”. There are an additional 267 Class II devices and 92 Class III devices. In comparison to the existing lists of which there were 488 Class II devices and 79 Class III devices. We take a look at what’s on the new list
Following the well publicised crackdown on drug trials, CFDA is now turning attention to devices and IVDs with a new program of audits and inspections.